However, there is another version in development (COP-2 really called PI-2301, which has been round the companies), which not a generic but a so called next generation drug.In EAE this is claimed to be better than COP-1. There are other more versions COP-3 or COP-4. One has a combination of tyrosine, phenylalanine, alanine, and lysine that binds better to the MHC complex, which is associated with susceptibility and MS.
They show that COP-2 (it’s not really called this:-)) works when you have subcutaneous injections but just like the COP-1, there is limited good animal data published to show that it blocks relapsing disease when administered subcutaneously after the attacks (is this secret data…just as it appears to be with COP-1?), yet it is already in clinical trials and has a name (Plovamer acetate).
Will it work ? Will it make it in the day of the pill?
Savinainen A et al. Differentiating Plovamer Acetate and Glatiramer Acetate: Efficacy and Mechanism of Action in a Preclinical Model of Multiple Sclerosis (P1.187)
Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Stern JN, Illés Z, Reddy J, Keskin DB, Sheu E, Fridkis-Hareli M, Nishimura H, Brosnan CF, Santambrogio L, Kuchroo VK, Strominger JL. Proc Natl Acad Sci U S A. 2004; 101(32):11743-8. Epub 2004 Aug 3.
Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Illés Z, Stern JN, Reddy J, Waldner H, Mycko MP, Brosnan CF, Ellmerich S, Altmann DM, Santambrogio L, Strominger JL, Kuchroo VK. Proc Natl Acad Sci U S A. 2004;101(32):
Amino acid copolymers that alleviate experimental autoimmune encephalomyelitis in vivo interact with heparan sulfates and glycoprotein 96 in APCs. Koenig PA, Spooner E, Kawamoto N, Strominger JL, Ploegh HL. J Immunol. 2013 Jul 1;191(1):208-16. doi: 10.4049/jimmunol.1300345. Epub 2013